Home

Michael R Hayden

CIK 1352908 · last filed 2026-08-24

Michael R Hayden is a corporate insider who has filed 65 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing shows the insider bought $570.4K of ABCL on Aug 24, 2026. Across all open-market trades the lifetime net is +$3.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $32.9M across reported positions. 23 SEC filings were submitted jointly with IONIS PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$32.92M

Companies

5

Total Filings

65

Lifetime Open-Market Net

$3.39M

Filer Profile

Reported Address
C/O ASPREVA PHARMACEUTICALS CORPORATION
1203-4464 MARKHAM STREET
VICTORIA, A1 V8Z 7X8
Related Filers
IONIS PHARMACEUTICALS INC — 23 joint filings, latest 2026-07-31
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ABCL Director 1,373,397 $11.41 $15.67M $250.0K 13 2026-08-24
IONS Director 73,298 $47.25 $3.46M $1.72M 21 2026-07-31
89bio, Inc. (ETNB) Delisted Director 0 $14.84 $0 $1.38M 11 2025-10-30
XENE Director 230,609 $56.28 $12.98M $41.2K 19 2021-06-03
AUPH Director 50,000 $16.13 $806.5K $0 1 2021-02-02

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-24 ABCL Buy (P) +53,613 $570.4K EDGAR
2026-08-14 ABCL Buy (P) +46,387 $481.0K EDGAR
2026-08-13 ABCL Gift (G) −50,000 $0 EDGAR
2026-07-31 IONS Buy (P) +20,000 $1.06M EDGAR
2026-07-06 IONS Grant (A) — $0 EDGAR
2026-06-12 ABCL Grant (A) — $0 EDGAR
2025-10-30 89bio, Inc. (ETNB) Delisted Mixed −246,420 $0 EDGAR
2025-07-17 IONS Exer (M) +4,079 $0 EDGAR
2025-07-02 IONS Grant (A) — $0 EDGAR
2025-07-01 ABCL Grant (A) — $0 EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.